{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(1)"],"submitter":["Kawahara T"],"pubmed_abstract":["<h4>Objective</h4>Recent preclinical and retrospective clinical evidence shows that androgen receptor (AR)-mediated signals have significant roles in development of non-muscle invasive bladder cancer (NMIBC). Here, we conducted a single-center, phase I study to assess the feasibility and efficacy of enzalutamide in patients having recurrent NMIBC with marker tumors. Patients with NMIBC who cannot achieve complete transurethral resection (TUR) or with recurrence within a year after the TUR, were enrolled. The patients were administered oral enzalutamide at 160 mg dose, once daily for four weeks. Clinical response at the end of the treatment was evaluated using cystoscopy.<h4>Results</h4>Of the six patients enrolled, two experienced multiple recurrences. All the patients received the planned"],"journal":["BMC research notes"],"pagination":["47"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11786325"],"repository":["biostudies-literature"],"pubmed_title":["Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study."],"pmcid":["PMC11786325"],"pubmed_authors":["Kawahara T","Kojima T","Nishiyama H","Mathis BJ","Shiga M","Kandori S"],"additional_accession":[]},"is_claimable":false,"name":"Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study.","description":"<h4>Objective</h4>Recent preclinical and retrospective clinical evidence shows that androgen receptor (AR)-mediated signals have significant roles in development of non-muscle invasive bladder cancer (NMIBC). Here, we conducted a single-center, phase I study to assess the feasibility and efficacy of enzalutamide in patients having recurrent NMIBC with marker tumors. Patients with NMIBC who cannot achieve complete transurethral resection (TUR) or with recurrence within a year after the TUR, were enrolled. The patients were administered oral enzalutamide at 160 mg dose, once daily for four weeks. Clinical response at the end of the treatment was evaluated using cystoscopy.<h4>Results</h4>Of the six patients enrolled, two experienced multiple recurrences. All the patients received the planned","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-01T10:26:21.053Z","creation":"2025-04-03T23:36:46.964Z"},"accession":"S-EPMC11786325","cross_references":{"pubmed":["39891237"],"doi":["10.1186/s13104-025-07128-z"]}}